Duodenal Ulcer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: DDN001 MIFTS: 54	Duodenal Ulcer Categories: Gastrointestinal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Duodenal Ulcer

MalaCards integrated aliases for Duodenal Ulcer:

Name: Duodenal Ulcer ¹¹ ⁵³ ⁴³ ¹⁴ ¹⁶ ⁷¹ ³¹ ³³

Stress Ulcer ¹¹ ⁵³ ⁷¹

Stress Ulcer of Stomach ⁷¹ ³³

Curling Ulcer ¹¹ ⁷¹

Duodenal Ulcer Disease ⁵³

Duodenal Peptic Ulcer ³³

Curling's Ulcers ¹¹

Duodenal Ulcers ¹⁴

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the digestive system

Diseases of oesophagus, stomach and duodenum

Duodenal ulcer

ICD11: ³³

Diseases of the digestive system

Diseases of the stomach or the duodenum

Ulcer of stomach or duodenum

Duodenal ulcer

Duodenal ulcer due to external causes

Duodenal ulcer due to external causes, unspecified

Duodenal ulcer due to other specified external causes

Duodenal ulcer, unspecified

Other specified duodenal ulcer

Gastric ulcer

Stress ulcer of stomach

External Ids:

Disease Ontology ¹¹ DOID:1724

ICD9CM ³⁴ 532

MeSH ⁴³ D004381

NCIt ⁴⁹ C26755

SNOMED-CT ⁶⁸ 155691003 39755000

ICD10 ³¹ K26

EFO ¹⁶ EFO_0004607

ICD11 ³³ 220699766 220699766/other 220699766/unspecified more

UMLS ⁷¹ C0010474 C0013295 C0400807 more

Sources

Summaries for Duodenal Ulcer

MalaCards based summary: Duodenal Ulcer, also known as stress ulcer, is related to gastric ulcer and pyloric stenosis. An important gene associated with Duodenal Ulcer is HRH2 (Histamine Receptor H2), and among its related pathways/superpathways are Signal Transduction and MIF Mediated Glucocorticoid Regulation. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and small intestine, and related phenotypes are nervous system and homeostasis/metabolism

Sources

Related Diseases for Duodenal Ulcer

Diseases in the Duodenal Ulcer family:

Duodenal Ulcer Due to Antral G-Cell Hyperfunction

Diseases related to Duodenal Ulcer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1065)

#	Related Disease	Score	Top Affiliating Genes
1	gastric ulcer	31.6	SST S100A8 IL6 HRH2 GAST CYP2C19
2	pyloric stenosis	31.3	SST MLN GAST
3	peptic ulcer perforation	31.2	S100A8 HRH2 GAST
4	cholecystitis	31.0	TLR4 S100A8 CCK
5	active peptic ulcer disease	31.0	SST HRH2 CYP2C19
6	duodenitis	30.9	TNF SST S100A8 INS GAST CCK
7	atrophic gastritis	30.8	SST SCT S100A8 IL1RN IL1B GAST
8	cholelithiasis	30.8	SST INS GAST CCK
9	pernicious anemia	30.8	SST INS GAST
10	opisthorchiasis	30.8	TNF IL1B CXCL8
11	hypoglycemia	30.7	SST SCT INS GAST
12	bile reflux	30.7	S100A8 GAST CCK
13	intestinal obstruction	30.7	TNF MLN IL6
14	zollinger-ellison syndrome	30.7	SST SCT MLN HRH2 GRP GAST
15	duodenogastric reflux	30.6	SST SCT MLN GAST CCK
16	duodenum cancer	30.6	SST SCT GAST
17	varicose veins	30.6	TNF IL6 CXCL8
18	common cold	30.6	TNF IL6 IL1B IL10 CXCL8
19	peritonitis	30.6	TNF TLR4 IL6 IL1B IL10 CXCL8
20	gastrointestinal system disease	30.6	S100A8 MLN GAST CCK
21	dumping syndrome	30.5	SST SCT MLN INS GAST CCK
22	hernia, hiatus	30.5	MLN INS HRH2 GAST CYP2C19
23	pulmonary tuberculosis	30.5	TNF TLR4 IL6 IL1B IL10
24	neurotic disorder	30.5	TNF INS IL6 IL1B
25	esophagitis	30.4	TNF MLN IL6 IL1B IL10 HRH2
26	inflammatory bowel disease 1	30.4	TNF TLR4 IL6 IL1B IL10
27	peptic esophagitis	30.4	TNF S100A8 MLN IL6 IL1B HRH2
28	purpura	30.4	TNF IL6 IL1B IL10 CXCL8
29	duodenum disease	30.4	SST SCT S100A8 GAST
30	appendicitis	30.4	TNF TLR4 S100A8 IL6 IL1B IL10
31	human cytomegalovirus infection	30.4	TNF IL6 IL10
32	exanthem	30.3	TNF IL6 IL1B IL10 CXCL8
33	paine syndrome	30.3	TNF IL6 IL1B IL10 CXCL8
34	haemophilus influenzae	30.3	TNF IL1B CXCL8
35	bronchopneumonia	30.3	TNF IL6 IL1B IL10 CXCL8
36	ileus	30.3	TNF IL6 IL1B IL10 CXCL1
37	cholangitis	30.3	TNF TLR4 SST IL6 IL10 CXCL8
38	gastrinoma	30.3	SST SCT INS GRP GAST
39	lymphoma, mucosa-associated lymphoid type	30.3	TLR4 S100A8 GAST CXCL8
40	achalasia	30.3	TNF LTA IL10 GRP GAST
41	gastroparesis	30.3	SST SCT MLN HRH2 GAST CCK
42	intestinal perforation	30.2	TNF IL6 IL10
43	alcohol use disorder	30.2	TNF TLR4 INS IL6 IL1B
44	food allergy	30.2	TNF IL10 CXCL8
45	angina pectoris	30.2	TNF INS IL6
46	liver cirrhosis	30.2	TNF SST SCT INS IL6
47	pneumonia	30.2	TNF TLR4 IL6 IL1B IL10 CXCL8
48	peptic ulcer disease	30.2	TNF SST SCT S100A8 INS IL6
49	biliary dyskinesia	30.2	SST SCT CCK
50	vasculitis	30.2	TNF IL6 IL1B IL10 CXCL8

Graphical network of the top 20 diseases related to Duodenal Ulcer:

Sources

Symptoms & Phenotypes for Duodenal Ulcer

GenomeRNAi Phenotypes related to Duodenal Ulcer according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.11	CCK CXCL1 CXCL8 CYP2C19 GAST GRP
2	no effect	GR00402-S-2	10.11	CCK CYP2C19 GAST HRH2 IL10 IL1B

MGI Mouse Phenotypes related to Duodenal Ulcer:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	10.1	CCK GRP HRH2 IL10 IL1B IL6
2	homeostasis/metabolism	MP:0005376	10.1	CCK CXCL1 GAST HRH2 IL10 IL1B
3	neoplasm	MP:0002006	9.91	GAST IL10 IL1B IL6 PSCA TLR4
4	digestive/alimentary	MP:0005381	9.76	GAST HRH2 IL10 IL6 INS SST
5	immune system	MP:0005387	9.73	CXCL1 GAST IL10 IL1B IL1RN IL6
6	skeleton	MP:0005390	9.32	CXCL1 IL10 IL1B IL1RN IL6 INS

Sources

Drugs & Therapeutics for Duodenal Ulcer

Drugs for Duodenal Ulcer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 65)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dexlansoprazole

Approved, Investigational

Phase 4

138530-94-6

9578005

Lansoprazole

Approved, Investigational

Phase 4

103577-45-3

3883

Amoxicillin

Approved, Vet_approved

Phase 4

26787-78-0

33613

Potassium citrate

Approved, Investigational, Vet_approved

Phase 4

866-84-2

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

23431961

Esomeprazole

Approved, Investigational, Vet_approved

Phase 4

73590-58-6, 119141-88-7

9568614 4594

Doxycycline

Approved, Investigational, Vet_approved

Phase 4

564-25-0

54671203

Ranitidine

Approved, Withdrawn

Phase 4

66357-59-3, 82530-72-1, 66357-35-5

3001055 5039

Sucralfate

Approved

Phase 4

54182-58-0

Pantoprazole

Approved

Phase 4

102625-70-7, 138786-67-1

4679

Famotidine

Approved

Phase 4

76824-35-6

3325 5702160

Histamine

Approved, Investigational

Phase 4

51-45-6

774

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Furazolidone

Experimental, Vet_approved

Phase 4

67-45-8

5323714

Bismuth tripotassium dicitrate

Phase 4

Bismuth

Phase 4

7440-69-9

105143

Citrate

Phase 4

Antibiotics, Antitubercular

Phase 4

Anti-Bacterial Agents

Phase 4

Anti-Infective Agents

Phase 4

Antiprotozoal Agents

Phase 4

Antiparasitic Agents

Phase 4

Expectorants

Phase 4

Antimalarials

Phase 4

Respiratory System Agents

Phase 4

Anti-Infective Agents, Local

Phase 4

Monoamine Oxidase Inhibitors

Phase 4

diuretics

Phase 4

Ranitidine bismuth citrate

Phase 4

Anti-Ulcer Agents

Phase 4

Antacids

Phase 4

Proton Pump Inhibitors

Phase 4

Gastrointestinal Agents

Phase 4

Neurotransmitter Agents

Phase 4

Histamine phosphate

Phase 4

51-74-1

134614

Histamine H2 Antagonists

Phase 4

Histamine Antagonists

Phase 4

Clarithromycin

Approved

Phase 3

81103-11-9

84029

Metronidazole

Approved

Phase 2, Phase 3

443-48-1, 69198-10-3

4173

Rabeprazole

Approved, Investigational

Phase 2, Phase 3

117976-89-3, 117976-90-6

5029

Rebamipide

Approved, Investigational

Phase 2, Phase 3

90098-04-7

5042

Cimetidine

Approved, Investigational

Phase 3

51481-61-9

2756

Ketoprofen

Approved, Vet_approved

Phase 3

22071-15-4

3825

Acetylsalicylic acid

Approved, Vet_approved

Phase 3

50-78-2

2244

Gefarnate

Investigational

Phase 3

51-77-4

3459

Cytochrome P-450 CYP3A Inhibitors

Phase 3

Analgesics

Phase 3

Cytochrome P-450 Enzyme Inhibitors

Phase 3

Antirheumatic Agents

Phase 3

Cyclooxygenase Inhibitors

Phase 3

Interventional clinical trials:

(show top 50) (show all 82)

#	Name	Status	NCT ID	Phase	Drugs
1	Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori	Unknown status	NCT01922765	Phase 4	amoxicillin, clarithromycin, metronidazole, rabeprazole
2	The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers: A Randomized, Parallel-controlled Multi-center Study	Completed	NCT03342456	Phase 4	Doxycycline Hyclate Enteric-Coated Capsules;Amoxicillin Capsules;Ilaprazole Enteric-Coated Tablets;Furazolidone Tablets;Potassium Citrate Tablets
3	Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection - A Combination of Clinical and Pharmacogenetic Study	Completed	NCT00854451	Phase 4	omeprazole plus amoxicillin
4	Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit	Completed	NCT00633035	Phase 4	esomeprazole 40 mg;famotidine 20 mg
5	Sup-Icu RENal (SIREN) - a Sub-analysis of the Prospective SUP (Stress Ulcer Prophylaxis)-ICU Trial on the Risk of GI- Bleeding in ICU Patients Receiving Renal Replacement Therapy	Completed	NCT02718261	Phase 4	Pantoprazole;Saline 0.9% (matching placebo)
6	Phase IV Study of Comparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial	Completed	NCT00708149	Phase 4	lansoprazole OD;placebo
7	A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia: a Randomized Prospective Study	Completed	NCT00702871	Phase 4	Ranitidine;Sucralfate
8	Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU)	Completed	NCT02467621	Phase 4	Pantoprazole
9	Effect of Prevacid on Prostaglandin Levels in the Gastric Mucosa of Patients With Stress Ulcer	Completed	NCT00239551	Phase 4	Prevacid
10	Stress Ulcer Prophylaxis Versus Placebo - a Blinded Randomized Control Trial to Evaluate the Safety of Two Strategies in Critically Ill Infants With Congenital Heart Disease	Completed	NCT03667703	Phase 4	Famotidine;Placebo
11	Effect of Intravenous Esomeprazole Versus Ranitidine on Gastric pH in Critically Ill Patients - a Prospective, Randomized, Double-Blind Study.	Completed	NCT00590928	Phase 4	esomeprazole;ranitidine
12	Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery	Terminated	NCT00839488	Phase 4	pantoprazole 40 mg iv;famotidine 20 mg iv
13	A Phase 3,Double-blinded, Double Dummy, Positive Drug, Parallel, Randomised Controlled Multicenter Trial to Evaluate Efficacy and Safety of Anaprazole Compared With Rabeprazole in Patients With Duodenal Ulcers.	Unknown status	NCT04215653	Phase 3	Anaprazole Sodium;Rabeprazole;Rabeprazole Placebo;Anaprazole Sodium Placebo
14	Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori	Unknown status	NCT00149084	Phase 3	Lansoprazole, clarithromycin, amoxicillin
15	Dual Therapy With High-Dose of Rabeprazole and Amoxicilline Versus Triple Therapy With Rabeprazole, Amoxicilline and Metronidazole as the Second Line Therapy for the Cure of H. Pylori Infection	Unknown status	NCT00197418	Phase 2, Phase 3	rabeprazole, amoxicillin, clarithromycin, metronidazole
16	A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20 mg Compared to Lansoprazole 30 mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Duodenal Ulcer Subjects With or Without Helicobacter Pylori Infection	Completed	NCT03050359	Phase 3	TAK-438;Lansoprazole;TAK-438 Placebo;Lansoprazole Placebo;Bismuth-Containing Quadruple Therapy
17	Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Omeprazole-Controlled,Multicenter,and Phase3 Trial in China	Completed	NCT00952978	Phase 3	10 mg ilaprazole;20 mg omeprazole
18	A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in Patients With Duodenal Ulcer	Completed	NCT01452724	Phase 3	TAK-438;Placebo;Lansoprazole
19	Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Rabeprazole-Controlled,Multicenterand Phase3 Trial in China in China	Completed	NCT02847455	Phase 2, Phase 3	5 mg ilaprazole;10 mg ilaprazole;10 mg Rabeprazole
20	A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy	Completed	NCT01568398	Phase 3	TAK-438
21	A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy	Completed	NCT01568385	Phase 3	TAK-438
22	A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric and Duodenal Ulcers During Long-term Treatment With Nonsteroid Anti-inflammatory Drug	Completed	NCT00787254	Phase 3	Lansoprazole;Gefarnate
23	A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of Esomeprazole(20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use	Completed	NCT00542789	Phase 3	Esomeprazole;Placebo
24	A Randomized, Double-blind, Parallel-group, Multicentre, Phase III Study to Assess the Effect of Esomeprazole 20 or 40 mg od Versus Placebo on the Occurrence of Peptic Ulcers During 26 Weeks in Subjects on Continuous Low Dose Acetylsalicylic Acid (ASA)	Completed	NCT00441727	Phase 3	Esomeprazole 40 mg;Esomeprazole 20 mg;Placebo
25	High Eradication Rates of Helicobacter Pylori With a New Sequential Treatment	Completed	NCT00132171	Phase 3	Sequential therapy
26	A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use	Completed	NCT00595517	Phase 3	Esomeprazole 20 mg
27	An Open-label, Parallel-group, Multi-centre, Phase I/III Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Once-daily Oral Administration of D961H 10 mg and D961H 20 mg in Japanese Paediatric Patients 1 to 14 Years Old With Gastrointestinal Acid Related Diseases	Completed	NCT02153398	Phase 3	D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
28	Cytoprotective Agent for Peptic Ulcer Prevention in Patients Taking Dual Antiplatelet Agents: A Randomized Double-blind Placebo Control Trial Study	Completed	NCT02166008	Phase 2, Phase 3	Repamipide;Placebo
29	A Phase III Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for Prevention of Gastric and/or Duodenal Ulcers Associated With Continuous Low-dose Aspirin (LDA) Use	Completed	NCT01069939	Phase 3	Esomeprazole;Placebo
30	A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin	Completed	NCT01452763	Phase 3	TAK-438;Placebo;Lansoprazole
31	A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID).	Completed	NCT01452750	Phase 3	TAK-438;Placebo;Lansoprazole
32	A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)	Completed	NCT01456260	Phase 3	TAK-438;Placebo;Lansoprazole
33	A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin	Completed	NCT01456247	Phase 3	TAK-438;Placebo;Lansoprazole
34	Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Open-label Trial-	Completed	NCT01398410	Phase 2, Phase 3	Rabeprazole
35	Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Double-blind Comparative Trial-	Completed	NCT01397448	Phase 2, Phase 3	E3810;Teprenone
36	Effect of Intravenous Esomeprazole Versus Cimetidine in Prevention of Stress Ulcer Prophylaxis in Chinese Seriously Ill Patients - a Randomized, Double-blind, Parallel-group Study	Completed	NCT02157376	Phase 3	Esomeprazole;Cimetidine
37	Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU	Completed	NCT02290327	Phase 3	Pantoprazole;Placebo
38	A Comparative Efficacy and Safety of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Placebo for the Prevention of Gastric and Duodenal Ulcers Associated With Daily NSAID Use in Patients at Risk	Completed	NCT00629928	Phase 3	Esomeprazole;Placebo
39	Safety, Tolerability and Efficacy of FDC Ketoprofen + Omeprazole in Patients With Rheumatological Conditions With History or Who Are at Risk of Developing NSAID Associated Benign Gastric Ulcers, Duodenal Ulcers and Gastroduodenal Erosions	Completed	NCT00971581	Phase 3	FDC KETOPROFEN+OMEPRAZOLE
40	A Multi-center, Randomized, Double-blind, Active-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LXI-15028 Compared to Lansoprazole in the Treatment of Duodenal Ulcer in Chinese Patients for up to 6 Weeks	Recruiting	NCT05010954	Phase 3	LXI-15028 50mg group;Lansoprazole 30mg group
41	An Open Label, Parallel Group, Multi-centre, Phase III Study to Assess the Efficacy and Safety of D961H for the Maintenance Therapy Following Initial Treatment in Japanese Paediatric Patients With Reflux Esophagitis and for the Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer in Japanese Paediatric Patients Treated With Non-steroidal Anti-inflammatory Drugs or Low-dose Aspirin	Active, not recruiting	NCT03553563	Phase 3	D961H capsule 10mg;D961H sachet 10mg
42	A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric And Duodenal Ulcers During Long-Term Treatment With Low Dose Aspirin.	Terminated	NCT00762359	Phase 3	Lansoprazole;Gefarnate
43	Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Omeprazole-Controlled,Multicenter,and Phase2 Trial in China	Completed	NCT00953381	Phase 2	5 mg ilaprazole;10 mg ilaprazole;20 mg ilaprazole;20 mg omeprazole
44	MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001)	Completed	NCT00543868	Phase 2	MK0782
45	A Phase 2,Double-blinded, Double Dummy, Positive Drug, Parallel, Randomised Controlled Multicenter Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.	Completed	NCT04503629	Phase 2	Anaprazole Sodium;Rabeprazole sodium
46	An Open Label, Randomised, Single Center, 2 Way Crossover Study to Assess Bioequivalence Between a Commercial HPMC Capsule of D961H 20 mg and a Pellets Based Sachet Formulation of D961H 20 mg by Pharmacodynamics (Intragastric pH) After Once-daily Repeated Oral Administration in Japanese Healthy Male Subjects	Completed	NCT01964131	Phase 1	D961H sachet 20 mg;D961H HPMC capsule 20 mg
47	Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers	Completed	NCT00284908	Phase 1	S-Tenatoprazole-Na (STU-Na)
48	An Open Label, Balanced, Randomized, Three-treatment, Three-period, Six-sequence, Cross-over, Single Dose, Comparative Bioavailability Pilot Study of Two Test Formulations of Fixed Dose Combination Capsules of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Manufactured by Piramal Healthcare Limited, India for GSK Comparing With Aspirin® Protect 100 mg Tablets by Bayer Vital GmbH, and Protium® 20 mg Gastro-resistant Tablets by Nycomed GmbH, in Healthy, Adult, Human Subjects, Under Fasting Conditions	Completed	NCT01847404	Phase 1	Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one;Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two;ASA 100 mg tablet;Pantoprazole 20 mg gastro-resistant tablet
49	An Open Label, Balanced, Randomized, Three-treatment, Three-period, Six-sequence, Cross-over, Single Dose, Comparative Bioavailability Pilot Study of Two Test Formulations of Fixed Dose Combination Capsules of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Manufactured by Piramal Healthcare Limited, India for GSK Comparing With Aspirin® Protect 100 mg Tablets by Bayer Vital GmbH, and Protium® 20 mg Gastro-resistant Tablets by Nycomed GmbH, in Healthy, Adult, Human Subjects, Under Fed Conditions	Completed	NCT01847417	Phase 1	Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one;Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two;ASA 100 mg tablet;Pantoprazole 20 mg gastro-resistant tablet
50	Efficacy and Safety of L-Pantoprazole Sodium Injection to Treat Upper Gastrointestinal Ulcer Bleeding	Unknown status	NCT02108756		L-pantoprazole sodium;Panmeilu

Search NIH Clinical Center for Duodenal Ulcer

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Aluminum carbonate

Aluminum Hydroxide

Aluminum Hydroxide / Magnesium Hydroxide

Aluminum Hydroxide Gel

aluminum hydroxide, dried (USP)

basic aluminum carbonate gel

Calcium Carbonate

CALCIUM CARBONATE 1 g in 1 g ORAL POWDER

Calcium gluceptate

Cimetidine

Cimetidine Hydrochloride

dihydroxyaluminum sodium carbonate

Esomeprazole

Esomeprazole magnesium

esomeprazole sodium

Esomeprazole Strontium

Famotidine

lansoprazole

magaldrate

Magnesium Hydroxide

Maprotiline

Maprotiline Hydrochloride

MILK OF MAGNESIA

Nizatidine

Omeprazole

Omeprazole 2 MG/ML Oral Suspension

Omeprazole magnesium

Prazepam

rabeprazole

Sucralfate

Cochrane evidence based reviews: duodenal ulcer

Sources

Genetic Tests for Duodenal Ulcer

Sources

Anatomical Context for Duodenal Ulcer

Organs/tissues related to Duodenal Ulcer:

MalaCards : Liver, Heart, Small Intestine, Pancreas, Adrenal Cortex, Colon, Lymph Node

Sources

Publications for Duodenal Ulcer

Articles related to Duodenal Ulcer:

(show top 50) (show all 21274)

#	Title	Authors	PMID	Year
1	Associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease in Chinese Han population. ⁵³ ⁶²	Mei Q...Hu YM	19804405	2010
2	Distribution of Helicobacter pylori virulence markers in patients with gastroduodenal diseases in Pakistan. ⁵³ ⁶²	Yakoob J...Islam M	19930551	2009
3	homB status of Helicobacter pylori as a novel marker to distinguish gastric cancer from duodenal ulcer. ⁵³ ⁶²	Jung SW...Yamaoka Y	19710266	2009
4	Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients. ⁵³ ⁶²	Miano TA...Bowton DL	19318661	2009
5	Serum antibodies positivity to 12 Helicobacter pylori virulence antigens in patients with benign or malignant gastroduodenal diseases--cross-sectional study. ⁵³ ⁶²	Filipec Kanizaj T...Mrzljak A	19399945	2009
6	Helicobacter pylori cagA status and peptic ulcer disease in Iran. ⁵³ ⁶²	Salehi Z...Mashayekhi F	18612816	2009
7	The prevalence of the duodenal ulcer promoting gene (dupA) in Helicobacter pylori isolates varies by ethnic group and is not universally associated with disease development: a case-control study. ⁵³ ⁶²	Schmidt HM...Mitchell H	19338650	2009
8	Prevalence of Helicobacter pylori pathogenicity-associated cagA and vacA genotypes among Pakistani dyspeptic patients. ⁵³ ⁶²	Ahmad T...Khanum A	19040660	2009
9	The prevalence of cagA and cagE genes in Helicobacter pylori strains isolated from different patient groups by polymerase chain reaction. ⁵³ ⁶²	Ghasemi A...Hosseini M	19260336	2008
10	Toll-like receptor (TLR2, TLR4 and TLR5) gene polymorphisms and Helicobacter pylori infection in children with and without duodenal ulcer. ⁵³ ⁶²	Moura SB...Magalhaes Queiroz DM	18809506	2008
11	IL-4 -588C>T polymorphism and IL-4 receptor alpha [Ex5+14A>G; Ex11+828A>G] haplotype concur in selecting H. pylori cagA subtype infections. ⁵³ ⁶²	Zambon CF...Plebani M	18179773	2008
12	Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report. ⁵³ ⁶²	Granberg D...Lehtihet M	18376130	2008
13	Effects of Helicobacter pylori Infection on gastric mucin expression. ⁵³ ⁶²	Kang HM...Song IS	18097286	2008
14	Helicobacter pylori environmental interactions: effect of acidic conditions on H. pylori-induced gastric mucosal interleukin-8 production. ⁵³ ⁶²	Choi IJ...Yamaoka Y	17517062	2007
15	Stress ulcer prophylaxis in hospitalized patients not in intensive care units. ⁵³ ⁶²	Grube RR...May DB	17592004	2007
16	Genetic polymorphisms of NOD1 and IL-8, but not polymorphisms of TLR4 genes, are associated with Helicobacter pylori-induced duodenal ulcer and gastritis. ⁵³ ⁶²	Hofner P...Mandi Y	17309748	2007
17	Helicobacter pylori cagA, vacA and iceA genotypes in northern Thai patients with gastric disease. ⁵³ ⁶²	Linpisarn S...Phornphutkul K	17539287	2007
18	Association between interleukin-1 gene polymorphisms and Helicobacter pylori infection in gastric carcinogenesis in a Chinese population. ⁵³ ⁶²	Li C...Xia B	17295877	2007
19	The risk of pancreatic cancer in patients with gastric or duodenal ulcer disease. ⁵³ ⁶²	Luo J...Ye W	17044024	2007
20	Analysis of serum antibody profile against H pylori VacA and CagA antigens in Turkish patients with duodenal ulcer. ⁵³ ⁶²	Erzin Y...Kocazeybek B	17106939	2006
21	[Expression of gastrin, somatostatin, PCNA and Fas-L in the mucosa of gastric antrum of children with chronic gastritis and duodenal ulcer]. ⁵³ ⁶²	Xie XZ...Hu WG	17229384	2006
22	Detection of Helicobacter pylori cagA gene in gastric biopsies, clinical isolates and faeces. ⁵³ ⁶²	Bindayna KM...Botta GA	16912439	2006
23	CagA positivity and its association with gastroduodenal disease in Turkish children undergoing endoscopic investigation. ⁵³ ⁶²	Sokucu S...Saner G	16868800	2006
24	Interaction between IL1B gene promoter polymorphisms in determining susceptibility to Helicobacter pylori associated duodenal ulcer. ⁵³ ⁶²	Chakravorty M...Roychoudhury S	16550552	2006
25	Assay of gastrin and somatostatin in gastric antrum tissues of children with chronic gastritis and duodenal ulcer. ⁵³ ⁶²	Xie XZ...Wang ZM	16610039	2006
26	Development of a novel method to detect Helicobacter pylori cagA genotype from paraffin-embedded materials: comparison between patients with duodenal ulcer and gastric cancer in young Japanese. ⁵³ ⁶²	Ueda H...Chayama K	16543737	2006
27	[The part of the hormone-cyclase system in achieving the therapeutic effect of hydrochloric acid secretion inhibitors at the duodenal ulcer]. ⁵³ ⁶²	Vahrushev IaM...Muravtseva OV	16866262	2006
28	IL1RN polymorphism and cagA-positive Helicobacter pylori strains increase the risk of duodenal ulcer in children. ⁵³ ⁶²	Queiroz DM...Carvalho AS	16183821	2005
29	No allelic variant associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease. ⁵³ ⁶²	Garcia-Gonzalez MA...Lanas A	16164697	2005
30	[Association of trefoil factor 1 expression with gastric mucosa injuries and gastric cancer]. ⁵³ ⁶²	Ren JL...Pan JS	16174594	2005
31	A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology. ⁵³ ⁶²	Salih BA...Sander E	16110845	2005
32	The humoral immuneresponse to Helicobacter pylori infection in children with gastrointestinal symptoms. ⁵³ ⁶²	Janulaityte-Gunther D...Andersen LP	15866217	2005
33	Relationship between trefoil factor 1 expression and gastric mucosa injuries and gastric cancer. ⁵³ ⁶²	Ren JL...Shi HX	15849833	2005
34	Down-regulation of epithelial IL-8 responses in Helicobacter pylori-infected duodenal ulcer patients depends on host factors, rather than bacterial factors. ⁵³ ⁶²	Stromberg E...Lindholm C	15762883	2005
35	Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. ⁵³ ⁶²	Zambon CF...Plebani M	15652446	2005
36	Topographic expression of MUC5AC and MUC6 in the gastric mucosa infected by Helicobacter pylori and in associated diseases. ⁵³ ⁶²	Marques T...Nogueira A	16325508	2005
37	[Gastrin-17 level in the omeprazole treatment of duodenal ulcer]. ⁵³ ⁶²	Belov DF...Loginov AF	17378383	2005
38	Gastric epithelial anti-microbial peptides--histological correlation and influence of anatomical site and peptic ulcer disease. ⁵³ ⁶²	Taha AS...Kelly RW	15702860	2005
39	Genetic polymorphism of interleukin-8 (IL-8) is associated with Helicobacter pylori-induced duodenal ulcer. ⁵³ ⁶²	Gyulai Z...Mandi Y	15627645	2004
40	TNF/LTA polymorphisms and risk for gastric cancer/duodenal ulcer in the Korean population. ⁵³ ⁶²	Lee SG...Song K	15381184	2004
41	High prevalence of multiple strain colonization of Helicobacter pylori in Korean patients: DNA diversity among clinical isolates from the gastric corpus, antrum and duodenum. ⁵³ ⁶²	Kim JW...Park SM	15053036	2004
42	The diversity of vacA and cagA genes of Helicobacter pylori in East Asia. ⁵³ ⁶²	Zhou W...Azuma T	14734191	2004
43	Helicobacter pylori-induced immunological responses in patients with duodenal ulcer and in patients with cardiomyopathies. ⁵³ ⁶²	Klausz G...Mandi Y	15571071	2004
44	Lewis antigen expression in gastric mucosa of children: relationship with Helicobacter pylori infection. ⁵³ ⁶²	Nogueira AM...Rocha AC	14676601	2004
45	Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer. ⁵³ ⁶²	Lehmann DF...Franklin PD	14615467	2003
46	Association of interleukin 1 gene family polymorphisms with duodenal ulcer disease. ⁵³ ⁶²	Garcia-Gonzalez MA...Pena AS	14632761	2003
47	[Effect of quamatel on neutrophil properties, parameters of lipid peroxidation and the antioxidant defense system in blood of patients with duodenal ulcer and pancreatitis]. ⁵³ ⁶²	Artiukhov VG...Basharina OV	14743716	2003
48	History in our lifetime: the changing nature of refractory duodenal ulcer in the era of histamine H2 receptor antagonists. ⁵³ ⁶²	Bardhan KD...Royston C	14567455	2003
49	Local and peripheral cytokine response and CagA status of Helicobacter pylori-positive patients with duodenal ulcer. ⁵³ ⁶²	Klausz G...Mandi Y	14656687	2003
50	DNA-level characterization of Helicobacter pylori strains from patients with overt disease and with benign infections in Bangladesh. ⁵³ ⁶²	Rahman M...Berg DE	12734242	2003

Sources

Genes for Duodenal Ulcer

Genes related to Duodenal Ulcer (0 elite genes):

(show all 25)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	HRH2	Histamine Receptor H2	Protein Coding	44.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8284002 7525198 14567455 (more) 9121092 1600048 2029801 8574733 1695268 12664778 2216957 1983413 10392669 10160472 9165690 10623364 19318661 17592004 1358868 8701013 1962941 9339962 1980184
2	GAST	Gastrin	Protein Coding	39.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1940201 1623579 8613042 (more) 1639220 9726392 2261695 2019363 1459351 2253822 1551523 9707051 2327380 1683324 9432354 7924733 8098023 16610039 8667697 8079929 2129824 1973394 8344574 7940604 8797269 17229384 8078239 8931414 2112442 11142576 7489932 1763293 8742644 8314507 8314506 1973962 8864424 8853766 7481540 1736336 11165229 8430271 7557570 1485981 2017311 7939393 1980809 1648649 2102978 17378383 10469191 9394759 9198884 7513113 1502485 2223248 7750184 12741450 10975785 9428218 8730264 7903471 1600044 8777296 7527257 8160143 10190251 8606137 8018978 1420739 1666696 2098841 2338186 18376130 8205594 8191737 8174954 1442334 1392340 1612474 16866262 11321891 10749086 9160210 8900906 7662416 7853818 8500723 1361654 1884735 8438856 2311972 12619573 11100382 9286242 11785198 7959081 9119420 9138823 8779096 11785199 1578802 1676714 2121423 11575448 9432338 8053437 8249971
3	S100A8	S100 Calcium Binding Protein A8	Protein Coding	37.83	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12697114 11843964 11158115 (more) 12734242 10950811 9759946 16868800 12435064 9666002 10548360 16543737 19710266 9398887 15053036 9577374 9748734 8677987 18612816 17539287 11030181 10425573 10716078 7881025 9922305 19399945 8547530 10499473 15652446 18809506 12593561 11253135 11175575 10669347 10535999 8567918 19260336 19040660 16912439 15866217 14734191 12795459 18179773 14656687 11252403 10710054 9832269 9774617 8780568 8188385 15571071 11325984 11316139 19930551 17106939 11321891 10802858 9136825 12358238 11427555 14676601 16110845 7650174 9706771
4	GRP	Gastrin Releasing Peptide	Protein Coding	29.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8098023 8174954 2019363 (more) 8779096 1763293 2141813 8730264 7737559 8707109 1612474 1639220 8613042 2253822 9432354
5	IL1RN	Interleukin 1 Receptor Antagonist	Protein Coding	24.15	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11531943 16164697 15652446 (more) 19804405 14632761 16183821 12788304 15381184 17295877 16550552
6	SST	Somatostatin	Protein Coding	22.51	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8098023 7924733 1352198 (more) 1973962 7903552 16610039 1977187 7939393 11575448 1977411 7903471 1982175 8777296 7853818 9394759 7787215 8779096 11100382 17229384 1980809 1357347
7	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	20.72	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17309748 15762883 9305491 (more) 11783237 9479649 10828748 11715460 19338650 9872512 17517062 8651162 14656687 15571071 11057919 15627645 9038594 10868450
8	CCK	Cholecystokinin	Protein Coding	18.82	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7939393 11305509 7851462 (more) 7787215 8185212 7489932 7668028 8714233 7481540
9	SCT	Secretin	Protein Coding	17.91	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10407222 17044024 1396006 (more) 1676864 8420745
10	CYP2C19	Cytochrome P450 Family 2 Subfamily C Member 19	Protein Coding	17.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14615467
11	CXCL1	C-X-C Motif Chemokine Ligand 1	Protein Coding	15.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9479649
12	IL1B	Interleukin 1 Beta	Protein Coding	15.53	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	TNF	Tumor Necrosis Factor	Protein Coding	15.31	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	LTA	Lymphotoxin Alpha	Protein Coding	14.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11781708 16164697
15	INS	Insulin	Protein Coding	14.18	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	IL6	Interleukin 6	Protein Coding	14.18	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
17	PSCA	Prostate Stem Cell Antigen	Protein Coding	14.14	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	IL10	Interleukin 10	Protein Coding	14.03	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	TLR4	Toll Like Receptor 4	Protein Coding	13.8	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	MLN	Motilin	Protein Coding	13.61	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
21	EGF	Epidermal Growth Factor	Protein Coding	13.32	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
22	NOD1	Nucleotide Binding Oligomerization Domain Containing 1	Protein Coding	13.32	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
23	MPO	Myeloperoxidase	Protein Coding	13.32	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
24	HLA-DRB1	Major Histocompatibility Complex, Class II, DR Beta 1	Protein Coding	13.24	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
25	CALCA	Calcitonin Related Polypeptide Alpha	Protein Coding	13.19	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Duodenal Ulcer

Sources

Expression for Duodenal Ulcer

Search GEO for disease gene expression data for Duodenal Ulcer.

Sources

Pathways for Duodenal Ulcer

Pathways related to Duodenal Ulcer according to GeneCards Suite gene sharing:

(show top 50) (show all 61)

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.74	CCK CXCL1 CXCL8 GAST GRP HRH2
2	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.65	CXCL1 CXCL8 IL10 IL1B IL1RN IL6
3	GPCR downstream signalling ⁶⁶ Show member pathways G alpha (i) signalling events ⁶⁶ G alpha (q) signalling events ⁶⁶ Signaling by GPCR ⁶⁶	13.61	SST SCT MLN HRH2 GRP GAST
4	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.44	CXCL1 CXCL8 IL10 IL1B IL6 LTA
5	Class A/1 (Rhodopsin-like receptors) ⁶⁶ Show member pathways GPCR ligand binding ⁶⁶ GPCRs, class A rhodopsin-like ⁷⁴ Peptide GPCRs ⁷⁴ Peptide ligand-binding receptors ⁶⁶	13.41	SST SCT MLN HRH2 GRP CXCL8
6	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.35	TNF LTA IL6 IL1RN IL1B IL10
7	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.32	TNF LTA IL6 IL1B IL10 CXCL8
8	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.85	TNF TLR4 IL6 IL1B CXCL8
9	NF-KappaB Family Pathway ⁶⁴ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁴	12.73	IL1B IL6 LTA TLR4 TNF
10	Malignant pleural mesothelioma ⁷⁴	12.71	INS IL6 IL1B IL10 CXCL1
11	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.67	TNF LTA IL6 IL1B IL10 CXCL8
12	IL-1 Family Signaling Pathways ⁶⁵ Show member pathways IL1 signaling pathway ⁶⁷ Immune response IL-1 signaling pathway ²² Interleukin-1 (IL-1) structural pathway ⁷⁴ Interleukin-33 signaling ⁶⁶ Interleukin-36 pathway ⁶⁶ Mucin expression in CF via TLRs, EGFR signaling pathways ²² Pathogen or Damage-activated C-Type Lectin Receptor Signaling Pathways ⁶⁵	12.65	TNF IL6 IL1RN IL1B CXCL8
13	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.62	TNF IL6 IL1B IL10 CXCL1
14	Toll-Like receptor Signaling Pathways ⁶⁵ Show member pathways Inflammasome Activation Pathways ⁶⁵ Nanomaterial-induced inflammasome activation ⁷⁴ NOD-like Receptor Signaling Pathways ⁶⁵ TLR4 signaling and tolerance ⁷⁴ Toll-Like Receptors Pathway ⁶⁴	12.56	TNF TLR4 IL6 IL1B CXCL8
15	Bacterial infections in CF airways ²² Show member pathways Altered glycosylation of MUC1 in tumor microenvironment ⁷⁴ IL-1 beta-dependent CFTR expression ²² IL1-mediated signaling events ⁶¹ Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²² NTHi-Induced Signaling ⁶⁴ Signal transduction through IL1R ⁷⁴	12.45	TNF TLR4 IL6 IL1RN IL1B CXCL8
16	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.36	CXCL8 IL1B IL6 TLR4 TNF
17	IL-17 Family Signaling Pathways ⁶⁵ Show member pathways IL17 signaling pathway ⁶⁷ IL-17 signaling pathway ⁷⁴ Mucin expression in CF via IL-6, IL-17 signaling pathways ²²	12.3	TNF IL6 CXCL8 CXCL1
18	Neuroinflammation and glutamatergic signaling ⁷⁴	12.14	IL10 IL1B IL6 LTA TNF
19	Spinal cord injury ⁷⁴	12.01	TNF TLR4 IL6 IL1B CXCL8 CXCL1
20	Interleukin-4 and Interleukin-13 signaling ⁶⁶	12	TNF IL6 IL1B IL10 CXCL8
21	Senescence and autophagy in cancer ⁷⁴	11.98	INS IL6 IL1B CXCL8 CXCL1
22	Cytokine production by Th17 cells in CF (Mouse model) ²² Show member pathways Cytokine production by Th17 cells in CF ²²	11.93	TLR4 IL6 CXCL8 CXCL1
23	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	11.93	TNF TLR4 LTA IL6 IL1B IL10
24	Allograft rejection ⁷⁴	11.92	TNF IL1B IL10 CXCL8
25	Sudden infant death syndrome (SIDS) susceptibility pathways ⁷⁴	11.9	TNF SST IL6 IL1RN IL1B IL10
26	Th17 Differentiation ⁶⁵ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.86	TLR4 IL6 IL1B
27	Innate Lymphoid Cells Differentiation ⁶⁵	11.85	TNF LTA IL1B IL10
28	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.81	TNF IL6 IL1B IL10
29	Activation of NF-KappaB by PKR ⁶⁴ Show member pathways Canonical NF-kB pathway ⁷⁴ Cellular Transformation by HTLV1 ⁶⁴ Inhibition of PKR ⁶⁶ STING pathway in Kawasaki-like disease and COVID-19 ⁷⁴	11.8	TNF LTA IL1B
30	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.79	TNF TLR4 IL6 IL10
31	Acute viral myocarditis ⁷⁴	11.77	TLR4 IL6 IL10
32	AP-1 transcription factor network ⁶¹	11.73	IL6 IL10 CXCL8
33	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.73	TNF IL6 IL1B CXCL8
34	Lung fibrosis ⁷⁴	11.72	TNF IL6 IL1B CXCL8
35	Inflammatory bowel disease signaling ⁷⁴ Show member pathways Ulcerative colitis signaling ⁷⁴	11.69	IL10 IL6 TLR4 TNF
36	miRNAs involvement in the immune response in sepsis ⁷⁴	11.69	TNF TLR4 IL6 IL10 CXCL8
37	Burn wound healing ⁷⁴	11.67	TNF TLR4 IL6 IL1B CXCL8 CXCL1
38	ATF-2 transcription factor network ⁶¹	11.65	INS IL6 CXCL8
39	Transcription_NF-kB signaling pathway ²²	11.62	TNF TLR4 LTA
40	SARS-CoV-2 innate immunity evasion and cell-specific immune response ⁷⁴	11.61	TNF IL10 CXCL8 CXCL1
41	Non-genomic actions of 1,25 dihydroxyvitamin D3 ⁷⁴	11.61	TNF TLR4 IL6 CXCL8
42	MSP-RON Signaling ⁶⁴	11.56	TNF TLR4 IL1B
43	Nonalcoholic fatty liver disease ⁷⁴	11.54	TNF INS IL6
44	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	11.53	TNF IL6 IL1B
45	Fibrin complement receptor 3 signaling pathway ⁷⁴	11.5	TNF TLR4 IL6
46	IL-10 Pathway ⁶⁴	11.37	TNF TLR4 IL6 IL1B IL10
47	Development and heterogeneity of the ILC family ⁷⁴	11.36	TNF IL6 IL1B
48	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway ⁷⁴	11.31	TNF IL6 IL1B CXCL8
49	Oligodendrocyte specification and differentiation, leading to myelin components for CNS ⁷⁴	11.3	TNF IL1B CXCL1
50	Cytokines and inflammatory response ⁷⁴	11.26	TNF IL6 IL1B IL10 CXCL1

Sources

GO Terms for Duodenal Ulcer

Cellular components related to Duodenal Ulcer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	10.13	CCK CXCL1 CXCL8 GAST GRP IL10
2	extracellular region	GO:0005576	9.83	CCK CXCL1 CXCL8 GAST GRP IL10

Biological processes related to Duodenal Ulcer according to GeneCards Suite gene sharing:

(show all 42)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of cell population proliferation	GO:0008285	10.31	CXCL1 CXCL8 IL10 IL1B IL6 SST
2	inflammatory response	GO:0006954	10.27	CXCL1 CXCL8 IL1B IL1RN IL6 S100A8
3	defense response to Gram-positive bacterium	GO:0050830	10.26	TNF LTA IL6 IL1B
4	positive regulation of DNA-binding transcription factor activity	GO:0051091	10.26	TNF IL6 IL1B IL10
5	positive regulation of inflammatory response	GO:0050729	10.24	IL1B S100A8 TLR4 TNF
6	positive regulation of interleukin-6 production	GO:0032755	10.23	TNF TLR4 IL6 IL1B
7	neutrophil chemotaxis	GO:0030593	10.21	CXCL1 CXCL8 IL1B S100A8
8	positive regulation of type II interferon production	GO:0032729	10.19	TNF TLR4 LTA IL1B
9	regulation of insulin secretion	GO:0050796	10.16	TNF IL6 IL1B
10	response to activity	GO:0014823	10.16	TNF IL6 IL10
11	positive regulation of nitric oxide biosynthetic process	GO:0045429	10.15	TNF TLR4 IL1B
12	positive regulation of interleukin-8 production	GO:0032757	10.15	TNF TLR4 IL6 IL1B
13	lipopolysaccharide-mediated signaling pathway	GO:0031663	10.14	TNF TLR4 IL1B
14	response to glucocorticoid	GO:0051384	10.14	TNF IL6 IL1RN IL10
15	positive regulation of NF-kappaB transcription factor activity	GO:0051092	10.14	TNF TLR4 S100A8 INS IL6 IL1B
16	positive regulation of receptor signaling pathway via JAK-STAT	GO:0046427	10.13	TNF IL6 IL10
17	positive regulation of cytokine production	GO:0001819	10.12	TNF INS IL1B IL10
18	positive regulation of mitotic nuclear division	GO:0045840	10.11	TNF INS IL1B
19	liver regeneration	GO:0097421	10.1	IL10 IL6 TNF
20	positive regulation of cytokine production involved in inflammatory response	GO:1900017	10.09	TNF TLR4 IL6
21	negative regulation of neurogenesis	GO:0050768	10.09	TNF IL6 IL1B
22	negative regulation of lipid catabolic process	GO:0050995	10.04	TNF INS IL1B
23	embryonic digestive tract development	GO:0048566	10.03	CXCL8 SCT TNF
24	positive regulation of chemokine production	GO:0032722	10.02	TNF TLR4 IL6 IL1B
25	response to lipopolysaccharide	GO:0032496	10.02	TNF TLR4 S100A8 LTA IL1B IL10
26	positive regulation of heterotypic cell-cell adhesion	GO:0034116	10	TNF IL1B IL10
27	negative regulation of interleukin-1-mediated signaling pathway	GO:2000660	9.98	IL6 IL1RN
28	positive regulation of oxidative stress-induced neuron death	GO:1903223	9.98	TNF TLR4
29	positive regulation of humoral immune response mediated by circulating immunoglobulin	GO:0002925	9.98	TNF LTA
30	negative regulation of cytokine production involved in immune response	GO:0002719	9.97	TNF IL10
31	positive regulation of fever generation	GO:0031622	9.97	IL1B TNF
32	cellular response to lipopolysaccharide	GO:0071222	9.97	TNF TLR4 IL6 IL1B IL10 CXCL8
33	sequestering of triglyceride	GO:0030730	9.95	TNF IL1B
34	positive regulation of neuroinflammatory response	GO:0150078	9.93	TNF IL6 IL1B
35	positive regulation of calcidiol 1-monooxygenase activity	GO:0060559	9.92	TNF IL1B
36	vascular endothelial growth factor production	GO:0010573	9.91	IL1B IL6 TNF
37	positive regulation of chronic inflammatory response to antigenic stimulus	GO:0002876	9.9	TNF LTA
38	chronic inflammatory response to antigenic stimulus	GO:0002439	9.89	TNF IL10
39	positive regulation of glial cell proliferation	GO:0060252	9.86	IL1B IL6 LTA TNF
40	immune response	GO:0006955	9.8	CXCL1 CXCL8 HRH2 IL10 IL1B IL1RN
41	signal transduction	GO:0007165	9.75	TNF TLR4 SCT MLN LTA INS
42	response to external stimulus	GO:0009605	9.69	TLR4 CXCL8 CXCL1

Molecular functions related to Duodenal Ulcer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	signaling receptor binding	GO:0005102	9.93	TNF TLR4 SCT LTA IL6 GRP
2	hormone activity	GO:0005179	9.73	SST SCT MLN INS GAST CCK
3	cytokine activity	GO:0005125	9.47	TNF LTA IL6 IL1RN IL1B IL10